Technical Analysis for IMMX - Immix Biopharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Fell Below 20 DMA | Bearish | 7.07% | |
| Down 3 Days in a Row | Weakness | 7.07% | |
| Fell Below 50 DMA | Bearish | -0.47% | |
| Upper Bollinger Band Touch | Strength | -0.47% | |
| 50 DMA Support | Bullish | -3.64% | |
| Inside Day | Range Contraction | -3.64% | |
| Upper Bollinger Band Touch | Strength | -3.64% | |
| 50 DMA Support | Bullish | -8.62% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 6 hours ago |
| Up 10% | about 8 hours ago |
| 50 DMA Resistance | about 8 hours ago |
| Rose Above 50 DMA | about 9 hours ago |
| Rose Above Previous Day's High | about 9 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. It is developing IMX-110 that is in Phase Ib/IIa clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. The company has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase Ib clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc. was incorporated in 2012 and is based in Los Angeles, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Ulcerative Colitis Sarcoma Abdominal Pain Crohn's Disease Soft Tissue Sarcoma
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Ulcerative Colitis Sarcoma Abdominal Pain Crohn's Disease Soft Tissue Sarcoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.75 |
| 52 Week Low | 1.55 |
| Average Volume | 124,369 |
| 200-Day Moving Average | 3.53 |
| 50-Day Moving Average | 2.16 |
| 20-Day Moving Average | 2.07 |
| 10-Day Moving Average | 2.11 |
| Average True Range | 0.21 |
| RSI (14) | 49.49 |
| ADX | 17.48 |
| +DI | 21.40 |
| -DI | 15.55 |
| Chandelier Exit (Long, 3 ATRs) | 1.82 |
| Chandelier Exit (Short, 3 ATRs) | 2.39 |
| Upper Bollinger Bands | 2.29 |
| Lower Bollinger Band | 1.84 |
| Percent B (%b) | 0.61 |
| BandWidth | 21.83 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.04 |
| MACD Histogram | 0.015 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.43 | ||||
| Resistance 3 (R3) | 2.42 | 2.30 | 2.38 | ||
| Resistance 2 (R2) | 2.30 | 2.22 | 2.31 | 2.36 | |
| Resistance 1 (R1) | 2.21 | 2.17 | 2.25 | 2.22 | 2.35 |
| Pivot Point | 2.09 | 2.09 | 2.11 | 2.10 | 2.09 |
| Support 1 (S1) | 2.00 | 2.01 | 2.05 | 2.02 | 1.89 |
| Support 2 (S2) | 1.88 | 1.96 | 1.89 | 1.88 | |
| Support 3 (S3) | 1.79 | 1.88 | 1.86 | ||
| Support 4 (S4) | 1.81 |
